Bipolar Disorder

For individuals prescribed antipsychotic medication, nonadherence, along with switching and stopping medication, was associated with increases in acute care utilization, according to a study published in BMC Psychiatry.

In children with familial high risk of schizophrenia or bipolar disorder, evidence of motor impairment skills may indicate neurodevelopmental vulnerability for psychosis.

The FDA has approved Rykindo for extended-release injectable suspension for the treatment of schizophrenia, as well as monotherapy or adjunctive therapy for the maintenance treatment of bipolar 1 disorder in adults.

In this video, Manpreet Kaur Singh, MD, MS, an associate professor of psychiatry and behavioral sciences at Stanford University, spoke with Healio about her presentation on diagnosing and treating bipolar disorder at the 2022 NEI Congress.

Mania was associated with reduced dopamine transporter density levels among those with bipolar disorder, researchers reported in JAMA Psychiatry.

The FDA has accepted a new drug application for aripiprazole, a 2-month, ready-to-use, long-acting injectable for the treatment of schizophrenia in adults and maintenance monotherapy treatment of bipolar I disorder in adults.

Introducing electroconvulsive therapy earlier in a treatment course for major depressive disorder or bipolar disorder may lead to improvements in clinical outcomes, according to a study published in the Journal of Clinical Psychiatry.

The FDA has provided guidance to biopharmaceutical company Alzamend Neuro Inc. regarding its development of an oral therapeutic to treat a range of psychological disorders.

French mental health diagnostics company Alcediag announced the results of a study that identified six blood biomarkers as major hallmarks of bipolar disorder.

BioXcel Therapeutics has announced the FDA approval of Igalmi, a sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.